drug

lemborexant

1 story · latest Sep 25, 2026

Status: FDA approved Dec 2019 · NDA212028
Brand: Dayvigo

Relationships

Developed by Eisai

Timeline

University of Alberta registers Phase 4 lemborexant nocturia trial with Eisai as collaborator

Sep 25Trial updateEisai lemborexant

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.